About BrainStorm Cell Therapeutics Inc male dysfunction pills.

About BrainStorm Cell Therapeutics Inc male dysfunction pills .BrainStorm Cell Therapeutics Inc. Is an emerging company that adult stem cell therapeutic products, from autologous stem bone marrow cells, for the treatment of neurodegenerative diseases. Of Neurology,TM) patent pending technology is based on discoveries by the scientific team of prominent neurologist Professor performed have Eldad Melamed based, Head of Neurology, Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. This technology enables the differentiation of bone marrow stem cells into functional neurons and astrocytes , as shown in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company will initially focus on Parkinson ALS and spinal cord injuries, although its technology holds promise for the treatment of some other diseases like MS, Huntington’s disease and stroke. – Safe Harbor Statement – Items in this announcement other than historical data and information constitute forward – looking statements that involve risks and uncertainties, lead to BrainStorm Cell Therapeutics Inc. ‘s. Materially from those materially from those stated or implied in such might forward-looking statements, including BrainStorm ‘s ability to complete, given the equity financing already known The potential risks and uncertainties include risks associated with BrainStorm Cell Therapeutics Inc. ‘s limited operating history, history of losses and anticipation can resort to losses for the foreseeable future, the dependence on its license to Ramot technology, the ability clinical trials clinical trials successfully and required regulatory approvals, together with its licensor, to identify to protect adequately the NurOwn technology, the dependence on key management and their professional advisors, to negotiate and successfully implement strategic partnerships relations, competition from companies some of which have greater resources and experience in the development and regulatory approval for treatments in BrainStorm Cell Therapeutics Inc. ‘s market, the limited public market for trading BrainStorm Cell Therapeutics Inc. ‘ s stock which may never develop into an active market, and other factors in BrainStorm Cell Therapeutics Inc. ‘s Annual Report on Form 10 – KSB, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the Securities and Exchange Commission or by request to detail the company. The company assumes no obligation to update forward-looking statements by us.

About OSAUnion more than 70 000 professionals from 134 countries, the Optical Society brings together the global optics community through its programs and initiatives. OSA publications, events, technical groups and programs foster optics knowledge and scientific collaboration among all that. An interest in optics and photonics For more information.

The WHO headquarters website provides a more information about measles , the Regional Office website provides information on:.